Vimarsana
Biggest News Aggregation in the World

Page 5 - Ellipses Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ellipses Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ellipses Pharma Today - Breaking & Trending Today

Gastric Cancer Pipeline Space Brims With Novel Emerging Therapies with Over 200 Key Companies Working in the Domain - Vimarsana News

Gastric Cancer Pipeline Space Brims With Novel Emerging Therapies with Over 200 Key Companies Working in the Domain

/PRNewswire/ -- DelveInsight's 'Gastric Cancer Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline...

Ellipses Pharma to present clinical updates at leading U.S. breast and blood cancer conferences - Vimarsana News

Ellipses Pharma to present clinical updates at leading U.S. breast and blood cancer conferences

Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, is delighted to announce that it will be presenting clinical updates covering two of its assets at the San Antonio Breast Cancer Symposium (SABCS), taking place between 6 – 10 ...

FDA approves Ellipses' IND for advanced RET-altered cancer treatment - Vimarsana News

FDA approves Ellipses' IND for advanced RET-altered cancer treatment

The US FDA has approved Ellipses Pharma’s investigational new drug (IND) application for EP0031 (A400) to treat advanced RET-altered cancers.

Ellipses Pharma: Ellipses Announces FDA Clearance of IND Application for EP0031 for Patients With Advanced RET-altered Malignancies - Vimarsana News

Ellipses Pharma: Ellipses Announces FDA Clearance of IND Application for EP0031 for Patients With Advanced RET-altered Malignancies

A phase 1/2 trial to initiate across a range of patient populations with RET-altered cancers Ellipses Pharma ("Ellipses"), a global drug development company focused on accelerating the development

Ellipses Pharma and SunRock Biopharma Enter Into a Licensing Agreement for a First-in-class Bifunctional HER3:TRAIL Fusion Protein - Vimarsana News

Ellipses Pharma and SunRock Biopharma Enter Into a Licensing Agreement for a First-in-class Bifunctional HER3:TRAIL Fusion Protein

Ellipses Pharma granted exclusive global rights to develop and commercialise SRB22, in solid tumours SunRock Biopharma S.L. ("SunRock"), a biopharmaceutical company that is developing a portfolio